Please assess the completion status of the following clinical trial:

Trial Title: S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed aggressive non-Hodgkin's lymphoma of 1 of the following subtypes:~  * Diffuse large B-cell~ * Mantle cell~ * High-grade B-cell, Burkitt's, or Burkitt-like~ * Anaplastic large cell (B-cell phenotype only)~* Stage I, IE, or non-bulky\* stage II or IIE disease by Ann Arbor classification~  * Patients who have bulky stage II or IIE disease are ineligible even if, after resection, the measurements are less than 10.0 cm NOTE: \*Non-bulky disease defined as any tumor measuring less than 10.0 cm or occupying less than 1/3 of the chest diameter~* CD20-expressing disease by flow cytometry or immunoperoxidase staining~* Aggressive lymphomas must have at least 1 of the following adverse prognostic factors:~  * Non-bulky stage II or IIE disease~ * At least 60 years of age~ * Zubrod performance status of 2~ * Lactic dehydrogenase greater than upper limit of normal~* All disease must be encompassable in a single radiation port (including any site of resected disease) NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of indolent or aggressive lymphoma will replace the former terminology of low, intermediate, or high grade lymphoma. However, this protocol uses the former terminology.~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No medical contraindication to study chemotherapy, rituximab, or ibritumomab tiuxetan~* No known AIDS syndrome or HIV-associated complex~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior monoclonal antibody therapy~Chemotherapy~* No prior chemotherapy for lymphoma~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~* No prior radiotherapy for lymphoma~* No concurrent intensity-modulated radiotherapy~* Planned involved-field radiotherapy must not encompass more than 25% of active bone marrow space~Surgery~* See Disease Characteristics~Other~* Concurrent participation in SWOG-8947 or SWOG-8819 allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CHOP + RT + Zevalin (Type: EXPERIMENTAL): Patients first receive 3 cycles (21 days each) of CHOP, consisting of: cyclophosphamide 750 mg/m\^2 on day 1, doxorubicin 50 mg/m\^2 on day 1, vincristine 1.4 mg/m\^2 on day 1, and prednisone 100 mg on days 1-5. Patients receive 4000-5000 cGy of radiation therapy in 25 fractions, starting 3 weeks after completion of CHOP. 3-6 weeks after completing RT, patients receive Zevalin, which consists of: rituximab 250 mg/m\^2 on days 1 and 7, 8 or 9; In-111 ibritumomab tiuxetan 5 mCi within 4 hours after rituximab on day 1; and Y-90 ibritumomab tiuxetan 0.4 mCi/kg within 4 hours after rituximab on day 7, 8 or 9.

Based on this trial design, predict the completion outcome and termination type (if applicable).